Our study attempted to identify the genetic risk factors associated with PU or ulcer bleeding. We investigated the identified 27 candidate SNPs of 23 genes associated with small bowel bleeding using DMET,[22] because these SNPs might be associated with GI bleeding including

PU bleeding among the patients taking LDA. Although these SNPs and additional two MK 1775 genes’ SNPS (ABCG2 c.421C > A(Q141K) rs2231142 and SLCO1B1*4_c.463C > A(P155T) rs11045819) for ulcer bleeding were investigated in our validation study, only the CHST2 SNP (rs6664) was significantly associated with ulcer or ulcer bleeding, as well as the SLCO1B1*1b haplotype. After adjustment for significant factors, the SLCO1B1*1b haplotype was Lumacaftor manufacturer associated with PU. Moreover, consistent with our previous reports,[6-8] cotreatment with statins or ARBs (or ACEIs) was significantly associated with PU and ulcer bleeding among patients taking LDA. A wide variety of anionic compounds, including statins, ACEIs, and ARBs, are actively transported from the portal blood into hepatocytes by OATP1B1, which is encoded by SLCO1B1.[15, 23, 24] Among the more than 40 mutations identified in SLCO1B1, A388G (Asn130Asp) and T521C (Val174Ala) occur frequently and have been extensively investigated. The T521C SNP has been consistently linked with reduced transport

activity of OATP1B1 both in vitro[15, 25-27] and in vivo,[23, 28, 29] and statin blood concentrations were reported to be higher in subjects with the 521C allele, which has been shown to be associated learn more with an increased risk of simvastatin-induced myopathy.[30] Two haplotypes with nonsynonymous variations, *1b harboring A388G and *15 harboring A388G and T521C, have been

frequently reported in Japanese. SLCO1B1*1b has been shown to have no altered transport activity from in vitro expression systems[15, 27, 31, 32]; however, an in vivo study suggested that the pravastatin blood concentration was significantly lower in *1b/*1b subjects than in *1a/*1a subjects.[33] Another major haplotype, SLCO1B1*15, has been reported to show impaired plasma membrane expression and reduced transport activity in vitro.[15, 27] Therefore, the SLCO1B1 521TT genotype as well as SLCO1B1*1b, which are thought to have the highest transport activity, may decrease statin and ARB blood concentrations and thus diminish the preventive effect of these drugs on aspirin-induced gastric mucosal injury, probably by reducing their concentrations in the stomach. We also found more significant difference in the frequency of the SLCO1B1*1b haplotype between the controls and not only the ulcer group, but also the bleeding group by analysis in the subgroup taking statins or ARBs; however, there was no significant difference in the subgroup not taking statins or ARBs. The SLCO1B1*1b haplotype could be a new risk marker for aspirin-induced mucosal injury especially in statin, ARB, or ACEI users.